Dr. Reddy's Laboratories Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDY research report →
Range $13.9 – $14.8
Price Chart
About the company
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions.
- CEO
- Erez Israeli
- IPO
- 2001
- Employees
- 27,527
- HQ
- Hyderabad, TS, IN
Get TickerSpark's AI analysis on RDY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.37B
- P/E
- 41.61
- Fwd P/E
- 0.34
- PEG
- -0.80
- P/S
- 3.53
- P/B
- 3.02
- EV/EBITDA
- 20.57
- Div Yield
- 0.57%
- Gross Margin
- 49.49%
- Op Margin
- 8.98%
- Net Margin
- 8.48%
- ROE
- 7.37%
- ROIC
- 4.83%
Latest fiscal year · YoY change
- Revenue
- $353.47B+8.6%
- Gross Profit
- $186.52B-2.1%
- Op Income
- $48.87B
- Net Income
- $45.09B-20.3%
- EPS
- $53.92-20.5%
- OCF Growth
- +22.0%
- FCF Growth
- +166.8%
- 52W High
- $15.67
- 52W Low
- $11.36
- 50D MA
- $13.28
- 200D MA
- $13.30
- Beta
- 0.25
- RSI (14)
- 68
- Avg Volume
- 2.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Dr. Reddy’s posted a mixed quarter: revenue fell 1.5% YoY, but the underlying business grew double digits excluding Lenalidomide and margins improved sharply from the prior quarter on a better mix and operating leverage.· October 23, 2026
- Revenue was ₹8.01 thousand crores ($905 million), down 1.5% YoY but up 7.4% sequentially.
- EBITDA margin came in at 20.6%, with reported gross margin at 52.1%; management said the underlying base business excluding Lenalidomide grew in double digits.
- North America fell 29% YoY to $264 million because of Lenalidomide, but the base business and new launches remained strong.
- India and emerging markets were key growth engines: India revenue rose 17.8% YoY and emerging markets grew 84% YoY.
- Management said semaglutide validation is on track for November 2026, while abatacept remains on track for FDA review with launch preparations underway.
Consolidated revenue was ₹8.01 thousand crores ($905 million), down 1.5% YoY and up 7.4% sequentially. EBITDA including other income was ₹17.83 crores ($186 million), with EBITDA margin at 20.6%, down 6 bps YoY and up 806 bps sequentially. Reported gross margin was 52.1% for the quarter, up 562 bps sequentially and down 254 bps YoY. PBT was ₹1 thousand crores ($128 million) and PAT attributable to equity holders was ₹9.25 crores ($97 million), with diluted EPS of ₹11.1. SG&A was ₹2.81 thousand crores, up 6% YoY and down 3% sequentially; R&D was ₹5.24 crores, down 16% YoY and 9% sequentially. Cash outflow for the quarter was ₹1.86 crores ($19 million), cash flow was ₹1.71 crores ($18 million), and net cash surplus was ₹2.5 thousand crores ($261 million). Forward guidance/comments: management said gross margin should stay in the 50% to 55% range; R&D should return to 7% to 8% of revenue in coming quarters; CapEx for the full year was guided at about ₹1.6 thousand crore to ₹1.7 thousand crore, versus an earlier guide of ₹1.8 thousand crore; semaglutide is expected to resume by November 2026 subject to validation; abatacept remains on track for a December 22 FDA goal date; NRT should grow in the high-single-digit to double-digit range; Europe ex-NRT should grow single digit this year; and CDMO could reach 2x to 3x current revenue levels in 3 to 4 years.
Erez Israeli emphasized that the company is staying focused on double-digit growth across geographies and sustainable profitability, driven by core execution, key assets, productivity, and both organic and inorganic growth. He said the quarter’s improvement came from business mix, with India, emerging markets, and NRT carrying higher profitability, plus higher-margin new products in the U.S. His tone was confident but cautious on pipeline timing, especially for complex generics and abatacept, where he repeatedly noted that approvals still depend on regulators.
Mannam Venkatanarasimham said the quarter’s revenue was ₹8.01 thousand crores ($905 million) and EBITDA margin was 20.6%, while gross margin reached 52.1%, within the company’s 50% to 55% range. He attributed the YoY margin pressure mainly to lower Lenalidomide sales and noted that SG&A was ₹2.81 thousand crores and R&D was ₹5.24 crores, with R&D expected to normalize to 7% to 8% of revenue in coming quarters. He also said operating working capital was $1.53 billion, net cash surplus was $261 million, and full-year CapEx is likely to be ₹1.6 thousand crore to ₹1.7 thousand crore.
Analysts pressed on semaglutide validation, Canada competition, and whether the company could still meet its launch and volume expectations; management said the API issue has been resolved, validation is still pending, and confidence is based on existing orders and shipments already sent to the partner. On abatacept, analysts asked about the FDA timeline, approval risk, and market-share potential; Erez said the goal date is December 22, the team feels good about the inspection and correspondence, but a CRL remains possible, and he estimated a fair U.S. market share of 15% to 25% for the IV launch, with subcutaneous later. Analysts also asked about margins, R&D, Europe, and NRT; management said the margin uplift came from mix and operating leverage, NRT should resume growth after the transition, and Europe ex-NRT should be only single-digit growth this year.
The call showed that the base business is still growing strongly even with Lenalidomide pressure, with India, emerging markets, and NRT helping offset North America weakness. Management sounded confident that semaglutide, abatacept, and a broader biosimilar/complex generics pipeline can support both growth and margins over time.
Reported revenue was still down YoY, and North America remains pressured by the Lenalidomide comparison. Several key catalysts still depend on regulatory and validation steps, especially semaglutide resumption and abatacept approval, and management acknowledged there is still a chance of a CRL for abatacept. Europe ex-NRT was soft, PSAI was muted, and management flagged continued cost pressure from raw materials, solvents, and freight through Q3 and Q4.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 833.38M
- Float Shares
- 833.38M
of shares held by institutions
242 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 24.29M | ▲ 13.36M |
| Royal Bank Of Canada | 9.21M | ▼ 770.81K |
| Blackrock, Inc. | 9.17M | ▼ 1.42M |
| Aikya Investment Management Ltd | 9.07M | ▲ 574.68K |
| Robeco Institutional Asset Management B.V. | 8.68M | ▼ 9.34M |
| Renaissance Technologies LLC | 6.98M | ▼ 364.50K |
| Franklin Templeton Inc | 6.40M | ▲ 3.55M |
| Dimensional Fund Advisors LP | 5.22M | ▼ 88.65K |
| Vanguard Group Inc | 5.03M | ▼ 96.44K |
| Jpmorgan Chase & Co | 4.46M | ▲ 395.58K |
| State Street Corp | 3.74M | ▼ 388.45K |
| Alliancebernstein L.P. | 3.73M | ▲ 1.19M |
Held by 160 ETFs
Biggest fund positions in RDY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | MUNNIRPALLAM MADHU SUNDAR SUBRAMANIAN | other | 0 |
| Dec 18, 25 | AGHANIAN PATRICK RUDOLF | other | 0 |
| Dec 18, 25 | KALAWADIA MILAN KANTILAL | other | 0 |
| Dec 18, 25 | MOTUPALLI VENKATA RAMANA | other | 0 |
| Dec 18, 25 | Israeli Erez | other | 0 |
| Dec 18, 25 | VENKATESH KRISHNA | other | 0 |
| Dec 18, 25 | KULKARNI SUSHRUT | other | 0 |
| Dec 18, 25 | BHETHANABOTTLA SRINIVASA PHANIMITRA | other | 0 |
| Dec 18, 25 | MANNAM VENKATA NARASIMHAM | other | 0 |
| Dec 18, 25 | SAPRA DEEPAK | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RDY coverage
Recent articles, reports, and earnings notes.
No research on RDY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDY report →RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
zacks.com · Oct 26
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 25
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
seekingalpha.com · Oct 23
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
marketbeat.com · Oct 23
Dr. Reddy’s Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?
defenseworld.net · Oct 15
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
prnewswire.com · Sep 24
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
globenewswire.com · Sep 22
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
reuters.com · Sep 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.